Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC

NCT07754812 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: Oral Paclitaxel Solution
DRUG: PD-1/PD-L1 inhibitor
RADIATION: Stereotactic Body Radiotherapy (SBRT)
PROCEDURE: Radical Lung Cancer Surgery
RADIATION: Stereotactic Body Radiotherapy (SBRT)

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China